Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure

Gastroenterology

Volumn 143, Issue 6, 2012, Pages

  Jeppesen, Palle B ^a   Pertkiewicz, Marek ^b   Messing, Bernard ^c   Iyer, Kishore ^d   Seidner, Douglas L ^e   O'Keefe, Stephen J D ^f   Forbes, Alastair ^g   Heinze, Hartmut ^h   Joelsson, Bo ⁱ  

^a Rigshospitalet   (Denmark)

^b Department of General Surgery and Clinical Nutrition ^*  (Poland)

^c BEAUJON HOSPITAL   (France)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h Nycomed GmbH   (Germany)

ⁱ Clinical Research and Development   (United States)

Author keywords

Clinical Trial; Gastrointestinal Disorder; Glucagon Like Peptide 2; Therapy

Indexed keywords

CITRULLINE; PLACEBO; TEDUGLUTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTESTINAL FAILURE; INTESTINE ABSORPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARENTERAL NUTRITION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT BOWEL SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; URINE VOLUME;

EID: 84869881880     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.09.007     Document Type: Article

References (22)

1. P.B. Jeppesen, P.B. Mortensen Intestinal failure defined by measurements of intestinal energy and wet weight absorption Gut 46 2000 701 706
2. B. Messing, F. Pigot, M. Rongier Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome Gastroenterology 100 1991 1502 1508
3. S.J. O'Keefe, A.L. Buchman, T.M. Fishbein Short bowel syndrome and intestinal failure: consensus definitions and overview Clin Gastroenterol Hepatol 4 2006 6 10
4. A.L. Buchman, J. Scolapio, J. Fryer AGA technical review on short bowel syndrome and intestinal transplantation Gastroenterology 124 2003 1111 1134
5. M. Wojdemann, A. Wettergren, B. Hartmann Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs Scand J Gastroenterol 33 1998 828 832
6. M. Wojdemann, A. Wettergren, B. Hartmann Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2 J Clin Endocrinol Metab 84 1999 2513 2517
7. L. Bremholm, M. Hornum, U.B. Andersen The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients Regul Pept 168 2011 32 38
8. P.D. Cani, S. Possemiers, T. Van de Wiele Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability Gut 58 2009 1091 1103
9. P.L. Brubaker, A. Izzo, M. Hill Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2 Am J Physiol 272 1997 E1050 E1058
10. P.B. Jeppesen, B. Hartmann, J. Thulesen Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon Gastroenterology 120 2001 806 815
11. P.B. Jeppesen, E.L. Sanguinetti, A. Buchman Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients Gut 54 2005 1224 1231
12. P.B. Jeppesen, R. Gilroy, M. Pertkiewicz Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome Gut 60 2011 902 914
13. P.B. Jeppesen, P. Lund, I.B. Gottschalck Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life Gastroenterol Res Pract 2009 2009 425759
14. P.B. Jeppesen, P. Lund, I.B. Gottschalck Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function Gastroenterol Res Pract 2009 2009 616054
15. P. Crenn, C. Coudray-Lucas, F. Thuillier Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans Gastroenterology 119 2000 1496 1505
16. J.S. Scolapio, A.D. Savoy, J. Kaplan Sleep patterns of cyclic parenteral nutrition, a pilot study: are there sleepless nights? JPEN J Parenter Enteral Nutr 26 2002 214 217
17. J. Thulesen, B. Hartmann, K.J. Hare Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice Gut 53 2004 1145 1150
18. C. Compher, R. Gilroy, M. Pertkiewicz Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome JPEN J Parenter Enteral Nutr 35 2011 603 609
19. A.P. Garrison, C.M. Dekaney, D.C. von Allmen Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion Am J Physiol Gastrointest Liver Physiol 296 2009 G643 G650
20. W. Tavares, D.J. Drucker, P.L. Brubaker Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats Am J Physiol Endocrinol Metab 278 2000 E134 E139
21. P.B. Jeppeson, E.L. Sanguinetti, A. Buchman Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients Gut 54 2005 1224 1231
22. P.B. Jeppesen Clinical significance of GLP-2 in short-bowel syndrome J Nutr 133 2003 3271 3724